Close Menu

research grant

The Solna, Sweden-based company is currently expanding from offering in situ sequencing services to selling kits.

The effort is focused on building an atlas of immune cell types found across a range of Asian population groups as part of the Human Cell Atlas project.

Technology partners on the study include BioMérieux and SkylineDx, as well as Imperial College London's biomedical electronics unit.

The funding, part of a larger initiative by Genome Canada, will support two studies in British Columbia that will evaluate genomics in healthcare.

The funding comes from the Bill and Melinda Gates Foundation, which previously provided the company with $500,000 for the test's initial development.

The funds will support the companies' efforts to develop tests for predicting NSCLC patients' response to immunotherapy.

Illumina, Twist Bioscience, and DNA Script are among the private sector collaborators of the groups receiving funds to develop technology platforms.

The researchers are aiming to provide new insights as to which cancer patients will respond best to immunotherapy based on their genetic backgrounds.

The center is responsible for developing and maintaining the technical platforms by which people participate in and engage with the program.

The clinical decision support content developer is integrating genetic testing information into its knowledgebase to assist physicians at the point of care.

Pages

Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.

Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.

A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.

In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.